Figure 4 | Scientific Reports

Figure 4

From: Mistletoe extract Fraxini inhibits the proliferation of liver cancer by down-regulating c-Myc expression

Figure 4

Cell growth inhibition activity of Fraxini in hepatocellular carcinoma (Hep3B and PLC/RF/5) and hepatoma HepG2 cells is dependent on c-Myc expression. (A) The anti-proliferative effects of Fraxini in aforementioned three liver cancer cell lines. (B) c-Myc levels in three liver cancer cell lines. (C) The expression of c-Myc in vector-transfected (Hep3B-Vec) and c-Myc siRNA–transfected Hep3B cells (Hep3B-c-Myc KD). (D) The proliferation of Hep3B-Vec and Hep3B-c-Myc KD cells treated with Fraxini. (E) Growth inhibition of Fraxini in hepatocellular carcinoma was observed in EC4 that conditionally express c-Myc and inactivate MYC by adding doxycycline (DOX, 20 ng/ml). Finally, Fraxini also reduced c-Myc protein expression in EC4 cells with c-Myc expression. (F) Data are presented as means ± SD. *p < 0.05 versus control vehicle treated; ap < 0.05 statistical different for the vehicle treated control cells between the groups.

Back to article page